Inclusion Criteria:

          -  Subjects must have histologically confirmed diagnosis of a non-small cell lung cancer,
             breast cancer, melanoma or renal cell cancer primary

          -  Subjects must have >5 contrast-enhancing lesions, never previously treated with SRS
             and/or surgical resection, on a contrast-enhanced T1-weighted brain MRI performed
             within two weeks of enrollment, with at least one lesion >0.5cm in greatest dimension

          -  Physical examination by a radiation oncologist or medical oncologist within 14 days of
             the start of WBRT

          -  Plan to be treated with WBRT to a dose of 30 Gy in 10 fractions

          -  Age * 18 years

          -  Karnofsky Performance Status (KPS) ≥ 70

          -  Hemoglobin ≥ 9.0 g/dl, ANC ≥ 1,500 cells/*l, platelets ≥ 125,000 cells/*l

          -  Serum creatinine ≤ 1.5 mg/dl, serum SGOT and bilirubin ≤ 1.5 times upper limit of
             normal

          -  Signed informed consent approved by the Institutional Review Board

          -  If sexually active, patients must agree to use appropriate contraceptive measures for
             the duration of the study and for 6 months afterwards as stated in the informed
             consent

          -  Able to provide study specific informed consent

          -  Willing to follow study procedures, complete QOL questionnaires and neurocognitive
             testing as described in the protocol

          -  Negative serum pregnancy test for women of child bearing potential within 48 hours of
             first dose of BMX

        Exclusion Criteria:

          -  Active infection requiring IV antibiotics 7 days before enrollment

          -  Hypertension requiring 3 or more anti-hypertensive medications to control

          -  Requirement for concurrent treatment with nitrates or other drugs that may, in the
             judgment of the treating investigator, create a risk for a precipitous decrease in
             blood pressure

          -  History of syncope within the last 6 months

          -  Subjects receiving prohibited medications listed in Section 6.4.2 of this protocol are
             not eligible. Subjects who can safely stop taking a prohibited medication at least 7
             days prior to the first dose of BMX may participate at the discretion of the treating
             physician.

          -  Pregnancy or women of childbearing potential and men who are sexually active and not
             willing/able to use medically acceptable forms of contraception; this exclusion is
             necessary because the treatment involved in this study may be significantly
             teratogenic

          -  Women who are breast feeding

          -  Known hypersensitivity to compounds of similar chemical composition to BMX-001

          -  Prior surgical resection for brain metastases and/or stereotactic radiosurgery for up
             to 5 brain metastases in total are permitted if performed at least 1 month prior to
             planned WBRT under this protocol.

          -  Prior whole brain radiation therapy

          -  Patients with diffuse leptomeningeal disease (carcinomatous meningitis)

          -  A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a
             QTc interval >480 milliseconds (ms) (CTCAE grade 1)

          -  A history of additional risk factors for TdP (e.g., congestive heart failure,
             hypokalemia, known family history of Long QT Syndrome)